



UCB's General Meeting of Shareholders

- For financial year 2018:
Gross dividend of € 1.21 per share (+ 2.5%), payable 30 April 2019
- All agenda items put to vote approved

Brussels (Belgium), 25 April 2019 – 18:00 (CEST) – regulated information - Today, UCB held its Annual General Meeting of Shareholders (AGM). At the AGM, 143 259 561 shares (76.07% of shares entitled to vote) were represented. During the course of this meeting, Jean-Christophe Tellier, Chief Executive Officer of UCB, gave the shareholders an overview of the financial year 2018 as well as the short and midterm perspectives for UCB including the six potential product launches in the next five years from UCB's clinical development pipeline. He also confirmed the financial outlook for 2019.

The AGM approved for the fiscal year 2018 the payment of a gross dividend of €1.21 per share (net dividend of €0.847 per share) compared to € 1.18 per share for 2017 (net € 0.826). The ex-dividend day is 26 April 2019, the dividend (coupon no. 22) will be payable on 30 April 2019.

The AGM re-appointed both Evelyn du Monceau and Cyril Janssen as directors and re-appointed Alice Dautry as independent director. Following her reappointment, Evelyn du Monceau remains chair of the Board of Directors of UCB. The AGM also appointed Jan Berger as new independent director. For the curriculum vitae of the Board members, please visit the UCB website: <https://www.ucb.com/investors/UCB-governance>.

All other agenda items put to vote at the AGM were approved by the shareholders present and represented. The minutes of the meeting including details of the votes will be available soon on UCB's website: <https://www.ucb.com/investors/UCB-shareholders>.

The Integrated Annual Report 2018 of UCB is available on UCB's website: <https://www.ucb.com/investors/Download-center>.

The financial results for the first half year 2019 will be published on 25 July 2019.

Next year's General Meeting will be held on 30 April 2020.

For further information

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T+32 2 559 95 88,
isabelle.ghellynck@ucb.com

Corporate Communications

France Nivelles,
Global Communications, UCB
T +32 2 559 91 78,
france.nivelles@ucb.com

Laurent Schots,
Media Relations, UCB
T +32 2 559 92 64,
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.